Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 2,451 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABI-007(Abraxane) Clear all
Recruiting Phase 3 Interventional

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

NCT07286331
View directory record Official record
Conditions
Neoplasms, Endometrial
Interventions
Mocertatug rezetecan, Paclitaxel, Doxorubicin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Birmingham, Alabama • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

NCT02109445
View directory record Official record
Conditions
Metastatic Cancer Pancreas
Interventions
PF-03084014, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Aurora, Colorado • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

NCT00006081
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Bryostatin-1, Paclitaxel (Taxol)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 1 Interventional Results available

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

NCT02597036
View directory record Official record
Conditions
Solid Tumors
Interventions
LY3127804, Ramucirumab, Paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Results available

A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies

NCT02412722
View directory record Official record
Conditions
Non-hematologic Malignancy
Interventions
Sapanisertib, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2Phase 3 Interventional

Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer

NCT00006229
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, rebimastat
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Results available

Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix

NCT00003377
View directory record Official record
Conditions
Cervical Cancer
Interventions
cisplatin, paclitaxel, brachytherapy, radiation therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
13
States / cities
Miami, Florida • Chicago, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

NCT02328105
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Abraxane
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545
View directory record Official record
Conditions
Human Mammary Carcinoma
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT01847001
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions
Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
Drug · Other · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

NCT01290380
View directory record Official record
Conditions
Solid Tumor Malignancies
Interventions
ASA404, DMXAA, DXAA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

NCT00019812
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Bethesda, Maryland • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 3 Interventional

Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer

NCT00251095
View directory record Official record
Conditions
Breast Neoplasm
Interventions
Taxol, TOCOSOL Paclitaxel
Drug
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Berkeley, California • Rancho Mirage, California • Stockton, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2009 · Synced Oct 24, 2026, 9:42 AM EDT
Not listed Not applicable Interventional

Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention

NCT01599078
View directory record Official record
Conditions
Restenosis, Peripheral Arterial Disease
Interventions
Paclitaxel, Placebo
Drug
Lead sponsor
Midwest Cardiovascular Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bettendorf, Iowa
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

NCT01632306
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LY2090314, FOLFOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

NCT01304784
View directory record Official record
Conditions
HER-2 Gene Amplification
Interventions
Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111, Lapatinib, trastuzumab, paclitaxel, and MM-111, Docetaxel, trastuzumab and MM-111
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 24, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

NCT04449549
View directory record Official record
Conditions
Neoplasms
Interventions
Nilotinib and Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 3 Interventional

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

NCT00003128
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
17
States / cities
Birmingham, Alabama • Stanford, California • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

NCT02080221
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Fairhaven, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

NCT02967133
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent
Interventions
Nivolumab, nab-paclitaxel
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Edgewood, Kentucky • Saint Louis Park, Minnesota • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT00564733
View directory record Official record
Conditions
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboplatin, docetaxel, gemcitabine hydrochloride, paclitaxel, computed tomography, positron emission tomography, fludeoxyglucose F 18, imaging biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 24, 2026, 9:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT01938833
View directory record Official record
Conditions
HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Romidepsin, Abraxane
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT01412229
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Nab-paclitaxel, Carboplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 24, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

NCT00003992
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
44
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 24, 2026, 9:42 AM EDT